Alberta Health - Drug Benefit List

Interactive Drug Benefit List

DIN/NPN/PIN 02274728 ENBREL 50 MG / SYR INJECTION SYRINGE ETANERCEPT

920000	MISCELLANEOUS THERAPEUTIC AGENTS
923600	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

Date Listed/Coverage Update:

Unit Price:

N/A

LCA Price:

N/A

MAC Price:

N/A

Unit of Issue:

Syringe

Manufacturer:

AMGEN CANADA INC. (AMG)

ATC:

L04AB01

Provincial Drug Schedule:

Interchangeable Products:

Yes

Coverage Status:	NOT A BENEFIT
Applies to Clients of:	N/A
Special Authorization Request Form:	N/A
Coverage Criteria:	N/A

Review Status / Past Decisions

Indication	Reviewing Body	Submission Completion Date	ADBL Effective Date	Review Status
N/A	Expert Committee	2021/05/01	2021/05/01	De-list
N/A	Expert Committee	2021/01/16	2021/01/15	De-list (for the indications of AS, PsA & RA)
N/A	Expert Committee	2021/01/15	2021/01/15	Special Authorization Criteria Change (pJIA, PsO)
N/A	Expert Committee	2020/11/19	2021/03/01	Special Authorization Criteria Change
N/A	Expert Committee	2020/09/22	2020/11/01	Special Authorization Criteria Change (Psoriasis)
N/A	Expert Committee	2020/08/23	2020/09/01	Special Authorization Criteria Change
PSORIASIS (MODERATE TO SEVERE CHRONIC PLAQUE)	Expert Committee	2020/02/01	2020/06/01	Special Authorization Criteria Change (Plaque Psoriasis)
PSORIASIS (MODERATE TO SEVERE CHRONIC PLAQUE)	Expert Committee	2020/02/01	2020/02/01	Special Authorization Criteria Change (Plaque Psoriasis)
OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)	Expert Committee	2008/11/12	2010/04/01	Special Authorization Criteria Change - Rheumatoid Arthritis
OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)	Expert Committee	2008/11/12	2010/04/01	Special Authorization Criteria Change - Juvenile Rheumatoid Arthritis
OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)	Expert Committee	2008/11/12	2009/03/04	Special Authorization Criteria Change (all listed indications except JRA)
OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)	Expert Committee	2008/11/12	2009/10/01	Special Authorization Criteria Change - Rheumatoid Arthritis
OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)	Expert Committee	2008/11/12	2012/08/01	Special Authorization Criteria Change - Rheumatoid Arthritis
ANKYLOSING SPONDYLITIS	Expert Committee	2008/02/12	2008/06/01	Special Authorization - Ankylosing Spondylitis
ANKYLOSING SPONDYLITIS	Expert Committee	2008/02/12	2008/05/01	Under Review - Ankylosing Spondylitis
ANKYLOSING SPONDYLITIS	Expert Committee	2007/08/15	2008/01/01	No Special Authorization Criteria Change - Ankylosing Spondylitis
N/A	Expert Committee	2007/02/14	2008/01/01	Under Review - Psoriasis
ARTHRITIS, JUVENILE IDIOPATHIC	Expert Committee	2007/02/14	2014/10/01	Special Authorization Criteria Change - Polyarticular Juvenile Idiopathic Arthritis
N/A	Expert Committee	2007/02/14	2008/07/01	Special Authorization - Psoriasis
N/A	Expert Committee	2007/02/14	2007/10/01	Special Authorization Criteria Change/Under Review - Rheumatoid Arthritis/Psoriasis
N/A	Expert Committee	2007/02/14	2007/07/01	Special Authorization Criteria Change/Under Review - Psoriatic Arthritis/Psoriasis
ARTHRITIS, JUVENILE IDIOPATHIC	Expert Committee	2007/02/14	2011/02/01	Special Authorization Criteria Change - Juvenile Idiopathic Arthritis
N/A	Expert Committee	2007/02/14	2008/04/01	Under Review - Psoriasis
N/A	Expert Committee	2007/02/14	2011/09/01	Special Authorization Criteria Change - Psoriasis
N/A	Expert Committee	2006/01/26	2006/10/01	Special Authorization - 50 mg/mL strength
N/A	Expert Committee	2006/01/26	2006/07/01	Under Review - 50 mg/mL strength

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2021/05/01
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2021/05/01
CDR Recommendation
Review Status	De-list

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2021/01/16
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2021/01/15
CDR Recommendation
Review Status	De-list (for the indications of AS, PsA & RA)

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2021/01/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2021/01/15
CDR Recommendation
Review Status	Special Authorization Criteria Change (pJIA, PsO)

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2020/11/19
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2021/03/01
CDR Recommendation
Review Status	Special Authorization Criteria Change

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2020/09/22
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2020/11/01
CDR Recommendation
Review Status	Special Authorization Criteria Change (Psoriasis)

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2020/08/23
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2020/09/01
CDR Recommendation
Review Status	Special Authorization Criteria Change

Indication	PSORIASIS (MODERATE TO SEVERE CHRONIC PLAQUE)
Reviewing Body	Expert Committee
Submission Completion Date	2020/02/01
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2020/06/01
CDR Recommendation
Review Status	Special Authorization Criteria Change (Plaque Psoriasis)

Indication	PSORIASIS (MODERATE TO SEVERE CHRONIC PLAQUE)
Reviewing Body	Expert Committee
Submission Completion Date	2020/02/01
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2020/02/01
CDR Recommendation
Review Status	Special Authorization Criteria Change (Plaque Psoriasis)

Indication	OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)
Reviewing Body	Expert Committee
Submission Completion Date	2008/11/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2010/04/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Rheumatoid Arthritis

Indication	OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)
Reviewing Body	Expert Committee
Submission Completion Date	2008/11/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2010/04/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Juvenile Rheumatoid Arthritis

Indication	OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)
Reviewing Body	Expert Committee
Submission Completion Date	2008/11/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2009/03/04
CDR Recommendation
Review Status	Special Authorization Criteria Change (all listed indications except JRA)

Indication	OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)
Reviewing Body	Expert Committee
Submission Completion Date	2008/11/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2009/10/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Rheumatoid Arthritis

Indication	OTHER (TWO OR MORE INDICATIONS BUT NOT ALL LISTED IN CURRENT PRODUCT MONOGRAPH)
Reviewing Body	Expert Committee
Submission Completion Date	2008/11/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2012/08/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Rheumatoid Arthritis

Indication	ANKYLOSING SPONDYLITIS
Reviewing Body	Expert Committee
Submission Completion Date	2008/02/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2008/06/01
CDR Recommendation
Review Status	Special Authorization - Ankylosing Spondylitis

Indication	ANKYLOSING SPONDYLITIS
Reviewing Body	Expert Committee
Submission Completion Date	2008/02/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2008/05/01
CDR Recommendation
Review Status	Under Review - Ankylosing Spondylitis

Indication	ANKYLOSING SPONDYLITIS
Reviewing Body	Expert Committee
Submission Completion Date	2007/08/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2008/01/01
CDR Recommendation
Review Status	No Special Authorization Criteria Change - Ankylosing Spondylitis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2008/01/01
CDR Recommendation
Review Status	Under Review - Psoriasis

Indication	ARTHRITIS, JUVENILE IDIOPATHIC
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2014/10/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Polyarticular Juvenile Idiopathic Arthritis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2008/07/01
CDR Recommendation
Review Status	Special Authorization - Psoriasis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2007/10/01
CDR Recommendation
Review Status	Special Authorization Criteria Change/Under Review - Rheumatoid Arthritis/Psoriasis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2007/07/01
CDR Recommendation
Review Status	Special Authorization Criteria Change/Under Review - Psoriatic Arthritis/Psoriasis

Indication	ARTHRITIS, JUVENILE IDIOPATHIC
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2011/02/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Juvenile Idiopathic Arthritis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2008/04/01
CDR Recommendation
Review Status	Under Review - Psoriasis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2007/02/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2011/09/01
CDR Recommendation
Review Status	Special Authorization Criteria Change - Psoriasis

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2006/01/26
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2006/10/01
CDR Recommendation
Review Status	Special Authorization - 50 mg/mL strength

Indication	N/A
Reviewing Body	Expert Committee
Submission Completion Date	2006/01/26
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date	2006/07/01
CDR Recommendation
Review Status	Under Review - 50 mg/mL strength

To return to the printable Drug Benefit List and related publications, click here

Last Updated:

NOTICE:

The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.